Investigational drug · Phase 2
AGN-193408
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Open-angle Glaucoma, Ocular Hypertension.
Phase 2Last checked: Nov 20, 2026Latest source record: May 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "AGN-193408"
First trial start
2020
Nov 16, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AGN-193408", any sponsor or status.
Conditions studied
As listed on its trial records.
- Open-angle Glaucoma
- Ocular Hypertension
Approved drugs for the same conditions: High blood pressure (hypertension) · Glaucoma · Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "AGN-193408" as an intervention, largest first.
- AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular HypertensionPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT04499248 · 100 participants · Start Nov 16, 2020 · Primary completion Apr 2029
Drug: AGN-193408 SR; AGN-193408 SR · For: Open-angle Glaucoma; Ocular Hypertension
Sites: Sun City, Arizona; Glendale, California; Inglewood, California · 49 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Open-angle Glaucoma
- PER-001 Intravitreal ImplantPhase 22 trials
Perfuse Therapeutics, Inc. · Diabetic Retinopathy, Open-angle Glaucoma
- PER-001 Intravitreal Implant - ShamPhase 22 trials
Perfuse Therapeutics, Inc. · Diabetic Retinopathy, Open-angle Glaucoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AbbVie.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.